Carriers and Antigens: New Developments in Glycoconjugate Vaccines

Area of Science:

• Vaccinology and Immunology
• Microbiology
• Synthetic Chemistry

Background:

• Glycoconjugate vaccines are effective in preventing infectious diseases, exemplified by the Haemophilus influenzae type b vaccine.
• These vaccines comprise a carrier protein and a carbohydrate antigen, with traditional antigens sourced from host extraction.
• Recent advancements focus on synthetic oligosaccharide production and bioconjugation techniques.

Purpose of the Study:

• To review the latest advancements in glycoconjugate vaccine development over the last five years.
• To highlight innovations in both carrier proteins and carbohydrate antigens.
• To discuss applications in combating antimicrobial resistance (AMR) and ESKAPE pathogens.

Main Methods:

• Literature review of scientific publications from the past five years.
• Analysis of novel carrier protein developments, including outer membrane vesicles, glycoengineered proteins, and virus-like particles.
• Evaluation of progress in synthetic carbohydrate antigen production and bioconjugation strategies.

Main Results:

• Identification of innovative carriers such as outer membrane vesicles, glycoengineered proteins, virus-like particles, protein nanocages, and peptides.
• Progress in the synthetic production of oligosaccharides and advancements in bioconjugation techniques for antigen development.
• Emerging applications of glycoconjugate vaccines against antimicrobial resistance (AMR) and ESKAPE pathogens.

Conclusions:

• Glycoconjugate vaccine technology is rapidly evolving with novel carriers and synthetic antigens.
• These advancements hold significant promise for addressing infectious diseases, particularly those caused by multidrug-resistant organisms.
• Continued research in synthetic biology and vaccinology will drive future vaccine innovations.